The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain

Brain Research

Volumn 1450, Issue , 2012, Pages 138-147

  McDonald, Jessica M ^a   Cairns, Nigel J ^b   Taylor Reinwald, Lisa ^b   Holtzman, David ^b   Walsh, Dominic M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid protein; Neuritic plaque; SDS stable A dimer; Water soluble A

Indexed keywords

AMYLOID BETA PROTEIN; DIMER; FORMIC ACID; MONOMER; TYLOXAPOL; WATER;

ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; DISEASE SEVERITY; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; PRIORITY JOURNAL; SENILE PLAQUE; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; BRAIN; FEMALE; HUMANS; MALE; PILOT PROJECTS; PLAQUE, AMYLOID;

EID: 84859434098     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2012.02.041     Document Type: Article

References (42)

1. D. Allsop, and J. Hardy Amyloid deposition as the central event in the aetiology of Alzheimer's disease Trends Pharmacol. Sci. 12 1991 383 388
2. D. Allsop The isolation and amino acid composition of senile plaque core protein Brain Res. 259 1983 348 352
3. P.V. Arrigada Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease Neurology 1992 631 639
4. G. Blessed The association between quantitative measures of dementia and senile change in the cerebral grey matter of elderly subjects Br. J. Psychiatry 114 1968 797 811
5. H. Braak, and E. Braak Neuropathological stageing of Alzheimer-related changes Acta Neuropathol. 82 1991 239 259
6. H. Braak Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry Acta Neuropathol. 112 2006 389 404
7. N. Cairns Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report Arch. Neurol. 66 2009 1557 1562
8. M. Cissé Reversing EphB2 depletion rescues cognitive functions in Alzheimer model Nature 469 2011 47 52
9. J.P. Cleary Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function Nat. Neurosci. 8 2005 79 84
10. B.J. Cummings, and C.W. Cotman Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity Lancet 346 1995 1524 1528
11. F.G. De Felice Abeta oligomers induce neuronal oxidative stress through N-methyl-d-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine J. Biol. Chem. 282 2006 11590 11601
12. D. Dickson Identification of normal and pathological aging in prospectively studied nondemeneted elderly individuals Neurobiol. Aging 13 1991 179 189
13. D. Freir Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites Nat. Commun. 2 2011 1341
14. G.G. Glenner, and C.W. Wong Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein Biochem. Biophys. Res. Commun. 120 1984 885 890
15. Y. He Two distinct ubiquitin immunoreactive senile plaques in Alzheimer's disease: relationship with the intellectual status in 29 cases Acta Neuropathol. 86 1993 109 116
16. C.R. Jack Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol. 9 2010 70299-6
17. S.M. Kanne Relating anatomy to function in Alzheimer's disease: neuropsychological profiles predict regional neuropathology 5 years later Neurology 50 1998 979 985
18. R. Katzman Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques Ann. Neurol. 23 1988 138 144
19. I. Klyubin Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization J. Neurosci. 28 2008 4231 4237
20. Y.-M. Kuo Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains J. Biol. Chem. 271 1996 4077 4081
21. 1-42 are potent central nervous system neurotoxins Proc. Natl. Acad. Sci. 95 1998 6448 6453
22. J. Lauren Cellular prion protein mediates impairment of synaptic plasticity by amyloid beta oligomers Nature 457 2009 1128 1132
23. L.F. Lue Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease Am. J. Pathol. 155 1999 853 862
24. D.M. Mann The progression of the pathological changes of Alzheimer's disease in frontal and temoral neorcortex examined both at biopsy and at autopsy Neuropathol. Appl. Neurobiol. 14 1988 177 195
25. C.L. Masters Amyloid plaque core protein in Alzheimer disease and Down syndrome Proc. Natl Acad. Sci. USA 82 1985 4245 4249
26. J. Mc Donald SDS-stable Aβ dimers extracted in the water- and triton-X100-soluble fractions of brain are specific for Alzheimer-type dementia Brain 133 2010 1297 1299
27. A.C. McKee Neuritic pathology and dementia in Alzheimer's disease Ann. Neurol. 30 1991 156 165
28. C.A. McLean Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease Ann. Neurol. 46 1999 860 866
29. D.L. Miller Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease Arch. Biochem. Biophys. 301 1993 41 52
30. S. Mirra The Consortium to Establish a Registry for Alzheimer's disease (CERAD) Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 1991 479 486
31. J. Naslund Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline J. Am. Med. Assoc. 283 2000 1571 1577
32. M. Renner Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5 Neuron 66 2010 739 754
33. D.J. Selkoe The molecular pathology of Alzheimer's disease Neuron 6 1991 487 498
34. G.M. Shankar Amyloid-beta dimers isolated directly from Alzheimer's disease brains impair synaptic plasticity and memory Nat. Med. 14 2008 837 842
35. G.M. Shankar Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life Neurobiol. Dis. 36 2009 293 302
36. M. Tabaton Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid Biochem. Biophys. Res. Commun. 200 1994 1598 1603
37. R.D. Terry Senile dementia of the Alzheimer type without neocortical neurofibrillary tangles J. Neuropathol. Exp. Neurol. 46 1987 262 268
38. R.D. Terry Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment Ann. Neurol. 30 1991 572 580
39. D. Walsh Naturally secreted oligomers of the Alzheimer amyloid β-protein potently inhibit hippocampal long-term potentiation in vivo Nature 416 2002 535 539
40. J. Wang The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging Exp. Neurol. 158 1999 328 337
41. G.K. Wilcock, and M.M. Esiri Plaques, tangles and dementia J. Neurol. Sci. 56 1982 343 356
42. W. Zhao, F.G. de Felice, S. Fernandez, H. Chen, M. Lambert, M.J. Quon, M.J. Quon, G.A. Krafft, and W.L. Klein Amyloid beta oligomers induce impairment of neuronal insulin receptors FASEB J. 22 2008 246 260